T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Nature Medicine
Katie J EwerOxford COVID Vaccine Trial Group

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed1. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses2 and might reduce the potential for disease enhancement3. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection4. Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. 5,6). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)7 given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single do...Continue Reading

Associated Clinical Trials

References

Jul 7, 1983·The New England Journal of Medicine·A J McMichaelP A Beare
Sep 24, 2013·Nature Medicine·Saranya SridharAjit Lalvani
May 6, 2014·Frontiers in Immunology·Sietske Rosendahl HuberDebbie van Baarle
Aug 27, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Susanne H HodgsonSimon J Draper
Dec 8, 2015·Expert Review of Vaccines·Patricia A JorqueraRalph A Tripp
Apr 7, 2017·European Journal of Immunology·Alansana DarboeMartin R Goodier
Oct 6, 2017·JAMA : the Journal of the American Medical Association·Hilary D MarstonAnthony S Fauci
Mar 29, 2020·The Journal of Clinical Investigation·Guang ChenQin Ning
Apr 13, 2020·Lancet· The Lancet
May 16, 2020·The Journal of Experimental Medicine·Georgina BowyerKatie J Ewer
Jun 9, 2020·Immunity·Nicolas VabretUNKNOWN Sinai Immunology Review Project
Jul 15, 2020·The New England Journal of Medicine·Lisa A JacksonUNKNOWN mRNA-1273 Study Group
Jul 31, 2020·Nature·Neeltje van DoremalenVincent J Munster
Aug 14, 2020·Immunity·Caroline AtyeoGalit Alter
Aug 14, 2020·Nature·Mark J MulliganKathrin U Jansen
Aug 18, 2020·Lancet·Sunil S Bhopal, Raj Bhopal
Aug 26, 2020·Nature Medicine·Diane Marie Del ValleSacha Gnjatic
Aug 30, 2020·Infection·Dominik WolffMichael Marschollek
Sep 2, 2020·The New England Journal of Medicine·Daniel F GudbjartssonKari Stefansson
Sep 6, 2020·Nature Reviews. Immunology·Mangalakumari JeyanathanZhou Xing
Dec 19, 2020·Nature Medicine·Jordan R BarrettUNKNOWN Oxford COVID Vaccine Trial Group

❮ Previous
Next ❯

Citations

Dec 19, 2020·Nature Medicine·Jordan R BarrettUNKNOWN Oxford COVID Vaccine Trial Group
Jan 18, 2021·International Journal of Biological Macromolecules·Dharma Rao TompaSaraboji Kadhirvel
Jan 23, 2021·Advanced Drug Delivery Reviews·Saborni ChakrabortyTaia T Wang
Jan 13, 2021·Nature Reviews. Immunology·Yvonne Bordon
Apr 6, 2021·Journal of Pharmaceutical Analysis·Congshan JiangShemin Lu
Apr 27, 2021·Current Opinion in Infectious Diseases·Janeri Fröberg, Dimitri A Diavatopoulos
May 28, 2021·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Takuto NogimoriTakuya Yamamoto
May 23, 2021·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam M SandorJenny P Y Ting
Apr 20, 2021·Rheumatology·Shuayb Elkhalifa, Hector Chinoy
May 29, 2021·Current Opinion in Virology·Drishya Kurup, Matthias J Schnell
Jun 3, 2021·Vaccines·Jang Hyun Park, Heung Kyu Lee
May 23, 2021·Human Immunology·Abhigyan ChoudhurySuprabhat Mukherjee
May 18, 2021·Journal of Neuroimmunology·Hannah KellyHesham Abboud
Jun 23, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Zaid A Alhinai, Nagi Elsidig
Jun 29, 2021·Expert Review of Vaccines·Chih-Cheng LaiPo-Ren Hsueh
Jul 3, 2021·Vaccines·Matthieu Van TilbeurghCaroline Manet
Jul 9, 2021·Frontiers in Immunology·Christina WoopenTjalf Ziemssen
Jul 2, 2021·BMJ : British Medical Journal·Chris Baraniuk
Jul 17, 2021·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Annemarie J F WestheimRonit Shiri-Sverdlov
Jun 15, 2021·Molecules and Cells·Min Kyung Jung, Eui-Cheol Shin
Jul 11, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hassan IzzedineKenar D Jhaveri
Jul 3, 2021·Nature Reviews. Immunology·Manish SadaranganiTobias R Kollmann
Aug 1, 2021·Inflammopharmacology·Ammara SaleemMohamed M Abdel-Daim
Aug 5, 2021·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Victoria G HallDeepali Kumar
Jul 30, 2021·Annals of Neurology·Frédéric ZuhornAndreas Rogalewski
Aug 21, 2021·Cellular & Molecular Immunology·Min-Seok Rha, Eui-Cheol Shin

❮ Previous
Next ❯

Methods Mentioned

BETA
antibody profiling
ELISA
flow cytometry
blood draw
density gradient centrifugation
FCS
FACS

Clinical Trials Mentioned

ISRCTN15281137
NCT04324606

Software Mentioned

GraphPad Prism
FlowJo
Gen5 ELISA

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.